This advancement extends the forensic window for identifying the substance in blood and urine samples.
The ability to detect GHB has historically been limited by its rapid metabolism. Previously, the substance was typically detectable in blood for only six hours and in urine for up to twelve hours, Schweizer Radio und Fernsehen (SRF) reported. This short timeframe often meant that by the time victims sought medical attention and provided samples, the drug had already been cleared from their systems.
The new methodology relies on the identification of a specific biomarker—a metabolic byproduct of GHB that persists in the body significantly longer than the parent compound.
- Extended Detection: The new testing protocol allows forensic experts to confirm GHB usage up to three days post-ingestion.
- Standardization: This biomarker integration is now part of the laboratory’s routine methodology, enabling more accurate analysis even when samples are collected a full day after an incident.
- Patient Urgency: Despite this technical progress, medical professionals maintain that early sample collection remains the gold standard for evidence preservation.
The efficacy of this biomarker was validated through controlled studies involving healthy volunteers. In these clinical trials, researchers administered GHB and monitored its clearance rate using the new analytical technique. The results indicated that the biomarker remained identifiable in all participants at the 28-hour mark. In the majority of cases, detection was possible two days after ingestion, with some samples remaining positive for up to three days.
“Through the biomarker, we can now make more concrete statements for longer,” Steuer told Schweizer Radio und Fernsehen (SRF). This integration effectively provides a wider diagnostic margin for forensic toxicologists, addressing a global challenge faced by legal medicine institutes attempting to verify cases involving non-consensual drug administration.
GHB is a central nervous system depressant that can cause rapid loss of consciousness, respiratory depression, and bradycardia (abnormally slow heart rate). Individuals who suspect they have been drugged should prioritize immediate emergency medical care. Do not wait for symptoms to resolve, as the pharmacological effects of GHB can be unpredictable and life-threatening when combined with other substances like alcohol.
When presenting at an emergency department, inform clinical staff immediately of the suspicion of drug-facilitated assault. Early clinical intervention is essential not only for toxicology screening but for addressing immediate physiological risks such as airway obstruction or cardiovascular instability. Forensic evidence collection requires specific protocols; therefore, seeking care at facilities equipped for sexual assault or toxicology forensic examination is recommended.
The limitations of GHB detection are not restricted to any single jurisdiction, making this research relevant to international forensic standards. By standardizing the use of this metabolic biomarker, the University of Zurich aims to provide a more reliable framework for analyzing cases that were previously deemed "inconclusive" due to delayed reporting.
The institute has now fully integrated this technique into its forensic workload, ensuring that current and future cases benefit from the extended diagnostic window.
